A Phase IV Study to Evaluate the Effect of Subcutaneous (SC) Tocilizumab Administered to Participants With Rheumatoid Arthritis (RA) Assessed Using Disease Activity Score (DAS28)

Study Overview
=================
Brief Summary
-----------------
The purpose of this clinical trial is to prospectively evaluate RA activity using the assessment of change in DAS28 under local conditions in Slovakia in participants who are treated with subcutaneously administered tocilizumab pursuant to the recommendations of the Ministry of Health of the Slovak Republic in order to better assess the disease activity and impairment of the joint function.

Official Title
-----------------
Prospective Evaluation of Rheumatoid Arthritis Activity Using DAS28 in Patients Treated With Subcutaneously Administered Tocilizumab on Local Level

Conditions
-----------------
Rheumatoid Arthritis

Intervention / Treatment
-----------------
* Drug: Tocilizumab


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Participants with age greater than or equal to (>=) 18 years Participants with moderate to severe active RA (DAS28 >=3.2) who did not respond sufficiently to or did not tolerate previous treatment with one or several disease-modifying antirheumatic drugs (DMARDs), irrespective of whether they were of biological or synthetic nature Participants eligible for the treatment with subcutaneously administered tocilizumab, as decided by the doctor in accordance with summary of product characteristics (SPC) and standard therapeutic procedures, who were not previously treated with tocilizumab and did not receive any other biological treatment for RA in the past either Assignment of participants for observation using the treatment described above is clearly separated from the physician's decision to prescribe the treatment to the patient. Pulmonologist's consent for chest X-ray and quantiferon test with commencement of biological treatment Exclusion Criteria: Hepatitis B surface antigen (HBsAg,) hepatitis C virus (HCV) or human immunodeficiency virus (HIV) positivity History of severe allergic or anaphylactic responses to human or humanized murine monoclonal antibodies History of intestinal ulcerations or diverticulitis Active hepatopathy with more than threefold increase of alanine transaminase (ALT) or aspartate transaminase (AST) Thrombocytes <100,000 per cubic milliliters (/mm^3), less than (<) 3,000 mm^3, absolute neutrophil count < 2,000 mm^3 Women of childbearing age (without medically confirmed sterility, e.g. following hysterectomy, ovariectomy, menopause lasting 2 years) who do not accept the use of a suitable form of contraception (e.g. barrier methods of contraception in the participant and partner, contraceptive pills or patches, hormonal implants, spermicidal agents in combination with barrier method of contraception, intrauterine device)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Tocilizumab<br>Participants will receive tocilizumab (162 milligrams [mg]) SC injection for 48 weeks. | Drug: Tocilizumab<br>* Tocilizumab will be administered at 162 mg SC injection for 48 weeks.<br>* Other names: RoActemra;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Average change from baseline in DAS28 |  | up to Week 24 | 
| Average change from baseline in DAS28 |  | up to Week 48 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percent of participants achieving clinical remission defined as a DAS28 <2.6 |  | Baseline, Week 12, 24, 36, and 48 | 
| Percentage of participants achieving a DAS28 >=3.2 |  | Baseline, Week 12, 24, 36, and 48 | 
| Evaluation of participant's pain using visual analogue scale (VAS) |  | Baseline, Week 12, 24, 36, and 48 | 
| Evaluation of the disease activity by participant using VAS |  | Baseline, Week 12, 24, 36, and 48 | 
| Evaluation of the disease activity by Doctor using VAS |  | Baseline, Week 12, 24, 36, and 48 | 
| DAS28-joint count (erythrocyte sedimentation rate) [DAS28(ESR)] score |  | Baseline, Week 12, 24, 36, and 48 | 
| DAS28-joint count (C-reactive protein) [DAS28(CRP)] score |  | Baseline, Week 12, 24, 36, and 48 | 
| Absolute and percent change in the Health Assessment Questionnaire (HAQ) |  | Baseline, Week 12, 24, 36, and 48 |